BIM-23190 (hydrochloride)

BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].

Product Specifications

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bim-23190-hydrochloride.html

Purity

99.33

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)N[C@@H](CCCCN)C(N[C@@H](CC)C(N[C@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)CSSC[C@H](NC([C@@H](CC5=CC=CC=C5)NC(CN6CCN(CCO)CC6)=O)=O)C4=O)=O)=O.Cl

Molecular Formula

C57H80ClN13O12S2

Molecular Weight

1238.91

References & Citations

[1]I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100 (9) :2386-92.|[2]Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297 (5) :E1078-88.|[3]T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285 (1) :95-104.